文献速递免疫规划传染病防控与疫情报告

20价肺炎球菌结合疫苗三批次在18-49岁成人中的免疫原性与安全性3期研究

A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
PubMed 文献 · Vaccine · 2021-07-24

这项3期随机双盲多中心研究将1710名未接种过肺炎球菌疫苗的18-49岁成人按2:2:2:1随机分配接种3个批次的PCV20或PCV13,评估免疫原性与安全性。结果显示3个批次PCV20对所有20种血清型的OPA几何平均滴度等效,免疫应答稳健,安全性与PCV13相似,多数事件为轻中度。

要点

  • 3个批次PCV20对全部20种疫苗血清型的OPA几何平均滴度均显示等效。
  • PCV20接种后OPA几何平均倍数升高、≥4倍升高比例及≥定量下限比例均显示稳健应答。
  • PCV20局部反应、全身事件和不良事件报告率与PCV13相似,多数为轻中度。

核心结论

  • 3个不同批次PCV20均显示稳健且一致的免疫原性。
  • PCV20的安全性和耐受性可接受,与PCV13相似。

研究设计与样本

  • 3期随机、多中心、双盲研究,纳入1710名未接种过肺炎球菌疫苗的18-49岁成人。
  • 参与者按2:2:2:1比例随机接种3个批次PCV20之一或PCV13。
  • 免疫原性通过接种前和接种后约1个月(28-42天)的血清型特异性OPA滴度评估。

主要发现

  • 3个PCV20批次对所有20种疫苗血清型的OPA几何平均滴度等效。
  • PCV20接种后观察到稳健应答,依据OPA几何平均倍数升高、≥4倍升高参与者百分比及OPA滴度≥定量下限参与者百分比评估。
  • 合并PCV20批次的局部反应、全身事件和不良事件报告率与PCV13相似,多数事件为轻中度。
  • PCV20组与PCV13组的严重不良事件和新诊断慢性疾病报告率均低且相似。

临床怎么用

  • 在18-49岁未接种肺炎球菌疫苗成人中,PCV20可诱导针对20种血清型的稳健免疫应答。
  • PCV20的安全性特征与PCV13相似,支持其在该人群中的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Introduction of pneumococcal conjugate vaccines (PCVs), including the 13-valent PCV (PCV13), has considerably reduced pneumococcal disease burden. However, additional serotypes not in PCV13 continue to present a substantial disease burden. The 20-valent PCV (PCV20) was developed to expand protection against pneumococcal disease beyond PCV13. As part of the phase 3 clinical development program, the current study assessed consistency of immune responses across 3 lots of PCV20 and described the safety profile of PCV20. METHODS: This phase 3, randomized, multicenter, double-blind study of pneumococcal vaccine-naive adults 18-49 years of age randomized 1710 participants in a 2:2:2:1 ratio to receive 1 of 3 lots of PCV20 or PCV13. Immunogenicity was assessed through serotype-specific opsonophagocytic activity (OPA) titers before and approximately 1 month (28-42 days) after vaccination. Reported local reactions within 10 days, systemic events within 7 days, adverse events (AEs) within 30 days, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination were evaluated. RESULTS: Equivalence in immune responses (OPA geometric mean titers) for all 20 vaccine serotypes was demonstrated across the 3 PCV20 lots. Robust responses, assessed by OPA geometric mean fold rises, percentage of participants achieving ≥4-fold rises, and percentage of participants with OPA titers ≥lower limit of quantitation, were observed after PCV20. Reported rates of local reactions, systemic events, and AEs were similar between the pooled PCV20 lots and PCV13; most events were mild or moderate. Reported rates of SAEs and NDCMCs were low and similar between the PCV20 and PCV13 groups. CONCLUSIONS: Three different lots of PCV20 demonstrated robust and consistent immunogenicity. The safety and tolerability of PCV20 was acceptable and similar to that of PCV13. (Clinicaltrials.gov: NCT03828617).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 2021. PMID: 34315611. doi:10.1016/j.vaccine.2021.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。